NEW YORK (GenomeWeb News) – KineMed has licensed GeneGo’s MetaCore software for an ongoing Phase II prognostic study of chronic lymphocytic leukemia, GeneGo said today.
 
KineMed is testing a biomarker of CLL flux as a predictor of disease course that is intended to stratify indolent versus aggressive disease.
 
MetaCore is GeneGo’s flagship product and is used for target selection and validation, identification of biomarkers for disease states, and toxicology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.